Novel therapies for inflammatory diseases

We are a clinical-stage biopharma company developing antibody therapeutics

Abcentra is developing a portfolio of treatment options targeting fewer side effects and better outcomes in addressing inflammation-related diseases.

Bullseye Icon

Target Inflammation

Our lead product, orticumab, targets oxLDL and associated inflammation without compromising immune system response.

How It Works

Antibody icon

Treat Disease

Orticumab is being developed to treat accelerated atherosclerosis and plaque psoriasis.

Learn More